Myasthenia Gravis Treatment Market Growth Trends and Forecast Through 2030

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Market Size Trajectory Of The Myasthenia Gravis Treatment Market From 2026 To 2030?

The myasthenia gravis treatment market has demonstrated significant growth in recent years. This market is projected to expand from $1.66 billion in 2025 to $1.79 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.8%. Historically, this expansion has been driven by the increasing prevalence of autoimmune disorders, the early adoption of corticosteroids, the widespread clinical use of cholinesterase inhibitors, the expansion of hospital-based MG treatment programs, and rising awareness of neuromuscular diseases.

The myasthenia gravis treatment market size is anticipated to experience substantial growth in the upcoming years, with projections indicating it will expand to $2.43 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.0%. This growth throughout the forecast period is primarily driven by advancements in monoclonal antibody development, increasing demand for minimally invasive surgery, the expansion of specialty clinics, a rising adoption of IVIG and advanced immunotherapies, and enhanced diagnostic capabilities through AI-based tools. Furthermore, major trends in the forecast period include the increasing uptake of immunosuppressive therapies, the growing utilization of monoclonal antibodies for MG treatment, a heightened preference for minimally invasive thymectomy, a greater demand for IVIG and plasmapheresis in severe cases, and the expansion of supportive and combination therapy approaches.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11980&type=smp

What Key Factors Are Shaping The Myasthenia Gravis Treatment Market Landscape?

An increasing incidence of myasthenia gravis is projected to drive expansion within the myasthenia gravis treatment market moving ahead. Myasthenia gravis is defined as an autoimmune neuromuscular disorder where individuals suffer from exhaustion and muscle weakness in their skeletal muscles. The treatment for myasthenia gravis encompasses delivering healthcare services and managing patient care to address the disease. Consequently, the rising occurrence of myasthenia gravis is escalating sales in the myasthenia gravis treatment market. For example, data from January 2024, provided by Myaware, a charity based in the UK, indicates that within a United Kingdom population of around 67,817,100, an estimated 22,855 people currently have myasthenia gravis, 204 are affected by Lambert-Eaton myasthenic syndrome, and 2,103 by congenital myopathies. This demonstrates that the increased prevalence of myasthenia gravis is fueling the expansion of the myasthenia gravis treatment market.

How Are Segments Identified Within The Myasthenia Gravis Treatment Market Segment Framework?

The myasthenia gravis treatment market covered in this report is segmented –

1) By Treatment: Anticholinesterase Agents, Immunosuppressants, Monoclonal Antibodies, Plasmapheresis Or Intravenous Immunoglobulin (IVIg), Thymectomy Or Surgical Options, Other Treatments

2) By Route Of Administration: Oral, Intravenous, Subcutaneous

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Or E-commerce

4) By End User: Hospitals, Clinics, Other End-Users

Subsegments:

1) By Anticholinesterase Agents: Pyridostigmine, Neostigmine, Ambenonium

2) By Immunosuppressants: Corticosteroids, Azathioprine, Mycophenolate Mofetil, Cyclosporine, Tacrolimus

3) By Monoclonal Antibodies: Eculizumab, Rituximab

4) By Plasmapheresis Or Intravenous Immunoglobulin (IVIg): Plasma Exchange Therapy, IVIg Infusions

5) By Thymectomy Or Surgical Options: Transsternal Thymectomy, Minimally Invasive Thymectomy, Robot-Assisted Thymectomy

6) By Other Treatments: Symptomatic Therapy, Complement Inhibitors, Experimental Therapies

What Market Trends Are Affecting The Myasthenia Gravis Treatment Market?

Major companies operating in the myasthenia gravis treatment market are directing their focus towards creating innovative products such as self-administered complement C5 inhibitors, aiming to improve treatment convenience, enhance patient autonomy, and lessen reliance on infusion-based care. These self-administered complement C5 inhibitors are defined as targeted autoimmune therapies developed for subcutaneous use, enabling patients to manage excessive complement activation by independently administering their treatment at home rather than within clinical infusion settings. As an instance, in October 2023, UCB Pharma, a Belgium-based pharmaceutical company, announced the US Food and Drug Administration (FDA)’s approval of Zilucoplan. This medication is utilized for treating adults with generalized myasthenia gravis (gMG) who are positive for anti-acetylcholine receptor (AChR) antibodies. This approval introduces a fresh option in the management of gMG, a condition characterized by muscle weakness resulting from an autoimmune response. ZILBRYSQ is notably a self-administered, once-daily subcutaneous complement C5 inhibitor, providing a convenient alternative to the traditional intravenous therapies that have served as the standard for gMG treatment.

Who Are The Companies Competing Within The Myasthenia Gravis Treatment Market?

Major companies operating in the myasthenia gravis treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., Biogen Idec, CSL Limited, Chugai Pharmaceutical Co. Ltd., Grifols S.A, UCB Inc., Mitsubishi Tanabe Pharma Corp., Genentech Inc., Horizon Therapeutics plc, Amneal Pharmaceuticals Inc., Argenx SE, Immunovant Inc., Cabaletta Bio Inc., RemeGen Co. Ltd., Kedrion SpA

Get The Full Myasthenia Gravis Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/myasthenia-gravis-treatment-global-market-report

Which Region Leads The Myasthenia Gravis Treatment Market In Overall Market Size?

North America was the largest region in the myasthenia gravis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myasthenia gravis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Myasthenia Gravis Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/myasthenia-gravis-treatment-global-market-report

Browse Through More Reports Similar to the Global Myasthenia Gravis Treatment Market 2026, By The Business Research Company

Muscle Spasticity Market Report 2026

https://www.thebusinessresearchcompany.com/report/muscle-spasticity-global-market-report

Duchenne Muscular Dystrophy Market Report

https://www.thebusinessresearchcompany.com/report/duchenne-muscular-dystrophy-global-market-report

Muscle Pain Treatment Market Report

https://www.thebusinessresearchcompany.com/report/muscle-pain-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795